1
Return

New insights from DAPA-CKD indicate dapagliflozin modulates key pathways related to kidney outcomes

delete2026-07-27
delete0
PRE
AI
M
Mark André de la Rambelje
N
Niels Jongs
P
Peter J. Greasley
R
Rasmus Ågren
P
Peter Rossing
D
David C. Wheeler
A
Ann Hammarstedt
C
C. David Sjostrom
A
Adriaan A. Voors
H
Hiddo J.L. Heerspink *
DOI：10.1016/j.kint.2026.06.043delete
deleteOriginal
deleteOriginal request for help
deleteShare
deleteSave
Abstract

Abstract

En 中文
Dapagliflozin improves kidney outcomes in patients with chronic kidney disease (CKD), yet the underlying mechanisms by which it exerts protective effects are not fully elucidated. Here, we applied plasma proteomics to identify proteins and pathways linked to CKD progression and examined which of these are modulated by dapagliflozin.

Journal

Kidney International cover
Kidney International
IF:
12.6
Papers:
1.6W
Citations:
4.8W

Organization

S
steno diabetes center
Scholars:
1.8K
Papers: 1.6K
Citations: 3
U
university college london
Scholars:
7.3K
Papers: 4.0K
Citations: 1
B
biopharmaceuticals r&d
Scholars:
51
Papers: 19
Citations: 0
U
university of groningen
Scholars:
4.7K
Papers: 2.0K
Citations: 0
Cited Papers

Cited Papers

Citing Papers

Citing Papers